Posted on

Exploring The Benefits of SS-31 Peptide | SS-31 Buy Now

SS-31 Buy

SS-31 Buy Now at the best price online. Choose Peptide Sciences, a company that specializes in the production and distribution of peptides, proteins, and amino acids for research purposes. Here are a few reasons why some researchers may choose Peptide Sciences:

Quality Assurance

Peptide Sciences is known for its commitment to providing high-quality products. They employ strict quality control measures to ensure the purity and integrity of their research chemicals. This includes employing analytical techniques such as mass spectrometry to verify the identity and composition of their products.

Product Selection

Peptide Sciences offers a wide range of research chemicals, including peptides, proteins, and amino acids. This variety allows researchers to find the specific compounds they need for their studies.

Reputation And Customer Reviews

Positive customer reviews and a good reputation in the research community can indicate a reliable supplier. It can be helpful to seek out feedback from other researchers who have used Peptide Sciences’ products to assess their experiences and satisfaction.

Secure Ordering And Packaging

Peptide Sciences typically ensures secure online ordering systems and packaging methods to maintain the integrity of the products during shipping. This helps to minimize the risk of contamination or degradation during transit.

Compliance With Regulations

It’s important to choose a supplier that complies with relevant regulations and guidelines for research chemicals. Peptide Sciences claims to adhere to these regulations, including the handling and distribution of their products in accordance with applicable laws.

It is crucial for researchers to conduct your own research and carefully evaluate any supplier before making a purchase. Consider factors such as the specific needs of your research, pricing, shipping options. Along, with the reputation of the company within the scientific community.

<<SS-31 Buy Now At The Best Price Online Today>>

Introduction To SS-31 Peptide

The SS-31 peptide, is also known as Elamipretide or Bendavia. It is a synthetic peptide that selectively targets the inner mitochondrial membrane. It has shown promise in preclinical studies for various diseases and conditions. This article provides an overview of what the SS-31 peptide is, how it works, and the potential benefits it offers in treating multiple disorders.

What Is SS-31 Peptide?

SS-31 peptide is a synthetic peptide that can penetrate cells and explicitly targets the inner mitochondrial membrane. Initially developed to address mitochondrial dysfunction-related diseases, such as neurodegenerative disorders, heart failure, and metabolic diseases, it has a unique amino acid sequence (D-Arg-2′,6′-dimethylTyr-Lys-Phe-NH2). This sequence allows it to bind to cardiolipin, a phospholipid found predominantly in the inner mitochondrial membrane, protecting mitochondrial function from oxidative stress.

What Is The Mechanism Of Action Of SS-31?

The primary mechanism of action of the SS-31 peptide involves its interaction with cardiolipin. Cardiolipin plays a vital role in maintaining the structure and function of the mitochondrial inner membrane. It helps stabilize mitochondrial membrane protein complexes, regulate membrane curvature, and preserve mitochondrial structure.

SS-31 peptide interacts with cardiolipin to influence membrane curvature and prevent damage caused by peroxidation, which can lead to mitochondrial dysfunction. It can enhance electron transport chain complex coupling, reduce the production of reactive oxygen species (ROS), and safeguard cardiolipin from peroxidative damage. These actions contribute to improved mitochondrial function and reduced oxidative stress in cells.

Potential Benefits Of SS-31 Peptide

Neurodegenerative Diseases

In preclinical studies focused on neurodegenerative diseases like Alzheimer’s and Parkinson’s, the SS-31 peptide has demonstrated promising results. These diseases are characterized by the accumulation of damaged mitochondria and increased oxidative stress, which can lead to neuronal cell death.

In cellular and animal models of Alzheimer’s disease, SS-31 peptide can enhance mitochondrial function, reduce ROS production, and protect against toxicity induced by amyloid-beta. Models of Parkinson’s disease has shown the ability to improve mitochondrial bioenergetics, reduce oxidative stress, and promote neuronal survival.

Heart Failure

SS-31 peptide has exhibited the potential to improve mitochondrial function in heart failure models. Heart failure can impair energy production and heighten oxidative stress in the heart. SS-31 peptide has shown signs of protecting the heart from ischemia-reperfusion injury, a significant cause of heart failure, by reducing ROS production, preserving mitochondrial function, and preventing cardiomyocyte death.

Furthermore, in animal models of dilated cardiomyopathy and ataxia syndrome (DCMA), a rare mitochondrial disease associated with heart failure. The SS-31 peptide can enhance cardiac function. In these models, it can reverse mitochondrial fragmentation, reduce ROS production, and improve cardiac function.

Metabolic Diseases

SS-31 peptide has shown potential in treating metabolic diseases like type 2 diabetes and obesity. In diabetic animal models, it has been observed to enhance mitochondrial function in skeletal muscle, liver, and heart tissues. It also reduces oxidative stress, improves glucose tolerance, and enhances insulin sensitivity. In obese animals, SS-31 peptide has been shown to increase fatty acid oxidation and energy expenditure, leading to weight reduction and improved metabolic health.

Other Diseases And Conditions

SS-31 peptide has demonstrated promise in addressing other diseases and conditions associated with mitochondrial dysfunction, such as:

  • Friedreich’s ataxia: In cellular models of Friedreich’s ataxia, the SS-31 peptide has been reported to upregulate frataxin expression, improve mitochondrial function, and protect against oxidative stress. Friedreich’s ataxia is a neurodegenerative disease associated with cardiomyopathy.
  • Acute kidney injury: Animal models have shown that SS-31 peptide can protect against ischemia-reperfusion-induced kidney injury. It achieves this by reducing ROS production and preserving mitochondrial function.
  • Age-related macular degeneration: SS-31 peptide has been found to protect retinal pigment epithelial cells from oxidative stress and mitochondrial dysfunction. It suggests potential benefits in age-related macular degeneration.

SS-31 Peptide Dosage

The optimal dose of SS-31 peptide for human use has yet to be established, as clinical trials are ongoing to evaluate its safety and effectiveness in various diseases. In preclinical studies, doses ranging from 1 to 10 mg/kg/day have been administered, depending on the specific model and disease. The peptide is typically delivered intravenously or subcutaneously, with treatment durations varying from a few days to several weeks.

What Are The Benefits Of SS-31 Peptide?

SS-31 peptide shows promise as a therapeutic agent for various diseases and conditions associated with mitochondrial dysfunction and oxidative stress. Targeting cardiolipin in the inner mitochondrial membrane offers potential benefits in treating neurodegenerative diseases, heart failure, metabolic diseases, and other conditions related to mitochondrial dysfunction.

However, it is essential to note that most studies have been preclinical, utilizing cellular and animal models. More research, including human clinical trials, is necessary to determine the safety, efficacy, and optimal dosage of SS-31 peptides for treating different human diseases and conditions.


Posted on

Buy ACE-083 Peptide For Research Neuromuscular Disorders

Buy ACE-083 Peptide

Ace-083 peptide is an investigational protein therapeutic designed to increase muscle mass and strength in specific muscles and muscle groups. It is being developed for diseases where improved muscle strength may provide a clinical benefit, such as inclusion body myositis and certain forms of muscular dystrophy. Ace-083 has attracted attention in the research community. This comprehensive guide will delve into the pharmacokinetics, mechanism of action, scientific studies, and potential applications of Ace-083. Plus, where to buy ACE-083 peptide for research use!

What is ACE-083?

ACE-083 is an investigational drug containing a modified form of human follistatin that binds myostatin and other muscle regulators. ACE-083 is a locally acting drug that has been shown to increase muscle growth in a clinical trial involving healthy postmenopausal women. The study administered ACE-083 unilaterally into rectus femoris or tibialis anterior muscles as one or two doses three weeks apart, and no serious adverse effects or dose-limiting toxicities occurred. ACE-083 may have the potential to increase muscle mass in a wide range of neuromuscular disorders. Study A083-02 is a Phase 2 clinical trial designed to evaluate the safety, tolerability, pharmacodynamics, efficacy, and pharmacokinetics of ACE-083 in patients with muscle weakness in certain conditions. 


Ace-083 is a locally acting follistatin-based therapeutic that binds myostatin and other muscle regulators, leading to increased muscle mass and force in neuromuscular disease mouse models. This first-in-human study examined these effects. Pharmacokinetics is the study of how a drug is absorbed, distributed, metabolized, and eliminated by the body. It involves examining the time course and magnitude of drug exposure in the body, as well as understanding factors that can affect drug concentration levels, such as age, gender, genetics, and co-administration with other drugs


Study Design

In a phase 1, randomized, double-blind, placebo-controlled, dose-ranging study in healthy postmenopausal women, Ace-083 (50-200 mg) or placebo was administered unilaterally into rectus femoris (RF) or tibialis anterior (TA) muscles as 1 or 2 doses 3 weeks apart.


Fifty-eight postmenopausal women were enrolled in the study, with 42 receiving Ace-083 and 16 receiving placebo. No serious adverse events (AEs), dose-limiting toxicities, or discontinuations due to AEs occurred. Maximum mean (± standard deviation [SD]) increases in RF and TA muscle volume were 14.5±4.5% and 8.9±4.7%, respectively. No significant changes in mean muscle strength were observed.


Ace-083 was well tolerated and resulted in significant targeted muscle growth. Ace-083 may have the potential to increase muscle mass in a wide range of neuromuscular disorders.

Mechanism of Action

FSHD is a disease characterized by the progressive weakening of muscles, starting in the face, shoulders, and upper arms. Ace-083 is designed to increase the strength and function of specific muscles.

How ACE-083 Works

The therapy contains a small molecule that binds to and inhibits select proteins in the TGF-beta protein superfamily, namely activins and myostatin, which reduce muscle growth. Normally, muscle size is controlled by a balance of building and breaking down muscle. Exercise helps muscles to grow. If a person stops exercising, the muscles gradually reduce in size due to the function of activins and myostatin, among other factors.

Inhibiting the TGF-beta family, sometimes called the “myostatin +” approach, reduces or slows muscle breakdown. This approach is thought to increase muscle mass and strength where the treatment is administered. Untreated muscles or other organs are not affected, which reduces the potential of side effects.

Scientific Studies With ACE-083

There have been multiple human and animal studies of Ace-083, pointing towards a correlation between its administration and local muscle growth.

ACE-083 is an investigational drug that has been studied in a Phase 2 clinical trial to evaluate its safety, tolerability, pharmacodynamics, efficacy, and pharmacokinetics.

The study aimed to increase muscle volume and improve functional outcomes in adults with FSHD, a slowly progressive muscular dystrophy. The study consisted of two parts: Part 1 was open-label ascending dose, assessing safety, and tolerability. While Part 2 was randomized, double-blind for six months, evaluating ACE-083240 mg/muscle vs placebo injected bilaterally every 3 weeks in the biceps brachii or tibialis anterior muscles, followed by six months of open-label.

The results showed that ACE-083 resulted in a significant increase in total muscle volume, but no consistent improvement in functional or PRO measures in either group. ACE-083 is a locally acting drug that works by increasing muscle growth in neuromuscular disorders. Furthermore, pharmacokinetics is the study of how a drug is absorbed, distributed, metabolized, and eliminated by the body.

Animal Studies

In one animal study, subjects were injected with Ace-083 twice per week, over four weeks. Findings indicated muscle growth localized to the site of injection.

Human Studies

Another study conducted on postmenopausal women provided similar findings. All 42 non-placebo subjects appeared to demonstrate higher muscle volume where Ace-083 was injected. Both of these studies show that this peptide may promote higher rates of muscle growth.

Ace-083 vs. Ace-031

Ace-083 works similarly to Ace-031; however, Ace-083 is designed to only increase muscle mass in the muscle that is treated.


Preclinical Studies

In preclinical animal studies, Ace-083 has shown selective and dose-dependent increases in muscle mass in treated muscles with no effects in untreated muscles.

Phase 2 Trial Results

Acceleron Pharma announced topline results from the phase 2 trial of Ace-083 in patients with Charcot-Marie-Tooth disease. Ace-083 did not achieve statistically significant improvements in functional endpoints relative to placebo. Acceleron has decided to discontinue the development of Ace-083.

Legal Status and Availability

Ace-083 is sold for research purposes only. It is intended for in vitro testing and laboratory experimentation only. Bodily introduction of any kind into humans or animals is strictly forbidden by law. This product is not for human use and can be harmful if ingested.

Warnings and Precautions

Ace-083 is a very potent research peptide. The product is not in a sterile solution and is not to be injected. This product should only be handled by licensed, qualified professionals. This product is not a drug, food, or cosmetic and should not be misbranded, misused, or mislabeled as a drug, food, or cosmetic.

Potential Applications

Despite the discontinuation of Ace-083’s development for Charcot-Marie-Tooth disease, its potential applications in other neuromuscular disorders are still being explored. Researchers are investigating the possibility of using Ace-083 to treat inclusion body myositis and certain forms of muscular dystrophy, where improved muscle strength may provide a clinical benefit.


Ace-083 is an intriguing investigational peptide that has shown potential in increasing muscle mass and strength in specific muscles and muscle groups. While its development for Charcot-Marie-Tooth disease has been discontinued, researchers continue to explore its potential applications in other neuromuscular disorders. As a potent peptide, Ace-083 should be handled with caution and used strictly for research purposes.



  1. MDA Strongly – FDA Grants Orphan Drug Designation to Acceleron Pharma’s Ace-083
  2. Neuromuscular Disorders Journal – Abstract
  3. Acceleron Pharma – Ace-083 Ligand Trap
  4. PubMed – First-in-human study of ACE-083
  5. Charcot-Marie-Tooth News – Preliminary CMT Phase 2 Trial Results
Posted on

Buy Prostamax: An Overview of Its Applications in Prostate Research

Buy Prostamax

Prostamax, a new tetrapeptide consisting of lysyl-glutamyl-aspartyl-proline. It has been increasingly recognized for its potential in treating chronic aseptic prostatitis and its complications. This article provides a comprehensive overview of Prostamax, its practical application in prostate research, and its comparison with other treatment methods. Plus, discover the best place where to buy Prostamax for research only.

Understanding Chronic Aseptic Prostatitis

Chronic aseptic prostatitis, also known as chronic bacterial prostatitis or chronic pelvic pain syndrome. It is the most common form of prostatitis, affecting men under 40-50 years old, characterized by recurrent pain in the pelvic region. It is often associated with psychosomatic disorders, neurosis, depression, and a significant reduction in the quality of life of affected individuals. Complications of chronic aseptic prostatitis include conditions of copulative and reproductive functions.

Prevalence and Current Treatment Methods

The prevalence of chronic aseptic prostatitis has been on the rise, despite the availability of numerous medical products for its treatment. Among the most popular prostatotropic medications are those derived from the extract of Serenoa repens and those created from extracts of the prostate, which represent a complex of biologically active peptides derived from the prostate of mature bulls.

The Emergence of Prostamax in Prostate Research

Prostamax, a new drug synthesized from peptides, has shown promise in treating chronic aseptic prostatitis. This tetrapeptide possesses tissue-specific effects on the prostate gland. It can reduce inflammation, prevent the development of sclerotic and atrophic processes, and improve sexual activity in experimental studies.


Experimental Methods and Animal Models

Experimental research on Prostamax has been conducted using white rats, specific males of the Wistar population, weighing between 330-500 grams and aged four months. Chronic aseptic inflammation of the prostate gland was induced in these rats through the suturing of the ventral share of the gland with a silk thread.

Comparator Agents: Prostamol Uno and Samprost

Two comparator agents were used in the experiments to evaluate the efficacy of Prostamax: Prostamol Uno and Samprost. Prostamol Uno, derived from the extract of Serenoa repens, is one of the most commonly used medical products for treating chronic aseptic prostatitis. Samprost, like Prostamax, is a bioregulatory peptide created from prostate extract.

Evaluating the Efficacy of Prostamax in Prostate Research

The experimental studies on Prostamax focused on several aspects, including its influence on mass, volume, and density of the ventral share of the prostate gland in rats. In addition studies look at its impact on morphometric indexes of the prostate gland.

Morphological and Morphometric Analysis

Morphological analysis showed that 45 days after the suturing procedure, the rats in the control group exhibited signs of chronic aseptic inflammation in the ventral share of the prostate gland. These signs included swelling, hyperemia of vessels, lymphoid infiltration of stroma, atrophy, and sclerosis, which increased the gland’s density.

The administration of Prostamax to the rats reduced the intensity of swelling, hyperemia, and cellular infiltration and blocked the development of sclerosal processes. Similar effects were observed in administering comparator agents, Prostamol Uno, and Samprost.

Comparison with Comparator Agents

While comparator agents were found to reduce inflammation and prevent the development of sclerotic processes, they could not prevent the development of atrophic processes in the prostate gland. Prostamax, on the other hand, effectively blocked the development of atrophic processes in the gland, making it a more efficient treatment option in experimental chronic abacterial prostatitis.

Advantages of Prostamax Over Existing Treatment Methods

The experimental results of Prostamax in the treatment of chronic aseptic prostatitis show several advantages over existing treatment methods:

Reduced Inflammation: Prostamax effectively reduces the intensity of swelling, hyperemia, and cellular infiltration in the prostate gland, leading to a more effective treatment for chronic aseptic prostatitis.

Prevention of Sclerotic and Atrophic Processes: Unlike comparator agents, Prostamax can block the development of both sclerotic and atrophic processes in the prostate gland, making it a more comprehensive treatment option.

Improved Sexual Activity: Prostamax has been shown to intensify the sexual activity of animals, making it a potential treatment option for sexual and reproductive function disorders associated with chronic aseptic prostatitis.


Prostamax has demonstrated promising results in experimental studies for treating chronic aseptic prostatitis, surpassing the efficacy of existing treatment methods derived from the extracts of Serenoa repens and the prostate. Its ability to reduce inflammation, prevent the development of sclerotic and atrophic processes, and improve sexual activity in animal models highlights its potential as a more effective treatment option for chronic aseptic prostatitis and its complications. Further research is necessary to validate these findings and explore the broader applications of Prostamax in the treatment of prostate-related disorders.


Chronic Aseptic Prostatitis: A Comprehensive Overview

Chronic aseptic prostatitis, also known as chronic pelvic pain syndrome (CPPS), is a complex condition that affects the prostate gland, causing persistent pelvic pain and discomfort. Unlike acute bacterial prostatitis, chronic aseptic prostatitis does not involve an active infection or the presence of bacteria in the prostate. This condition poses significant challenges in diagnosis, treatment, and management.

Symptoms: The symptoms of chronic aseptic prostatitis can vary from person to person but typically include:

  1. Pelvic pain or discomfort: Persistent pain in the pelvic region, which may be dull, aching, or throbbing in nature. The pain can fluctuate in intensity and duration.
  2. Urinary problems: Frequent urination, urgency, hesitancy, weak urine flow, and a feeling of incomplete bladder emptying.
  3. Sexual dysfunction: Erectile dysfunction, pain during ejaculation, decreased libido, and discomfort in the genital area.
  4. Psychological impact: Chronic pelvic pain can lead to emotional distress, anxiety, and depression.

Causes: The exact cause of chronic aseptic prostatitis is still not fully understood. Several factors contribute to its development, including:

  1. Inflammation: Chronic inflammation within the prostate gland and surrounding tissues may play a significant role in developing symptoms.
  2. Autoimmune response: Some researchers propose that an autoimmune response may trigger an inflammatory reaction in the prostate, leading to chronic pelvic pain.
  3. Nerve dysfunction: Nerve abnormalities or dysfunction in the pelvic region may contribute to the pain experienced in chronic aseptic prostatitis.

Diagnosis and Treatment: Diagnosing chronic aseptic prostatitis can be challenging, as no specific tests or biomarkers are available. The diagnosis is typically made based on the patient’s reported symptoms, medical history, physical examination, and ruling out other possible causes of pelvic pain.

Treatment options for chronic aseptic prostatitis focus on managing symptoms and improving quality of life. They may include:

  1. Medications: Nonsteroidal anti-inflammatory drugs (NSAIDs), alpha-blockers, muscle relaxants, and low-dose antidepressants can help to alleviate pain and improve urinary symptoms.
  2. Physical therapy: Techniques such as pelvic floor muscle relaxation exercises, trigger point release, and biofeedback therapy can help reduce muscle tension and pelvic pain.
  3. Lifestyle modifications: Dietary changes, stress management techniques, regular exercise, and avoiding irritants (caffeine, alcohol) may relieve symptoms.
  4. Psychological support: Counseling, cognitive-behavioral therapy, and relaxation techniques can assist in managing the psychological impact of chronic pelvic pain.

Research on Prostamax and Chronic Aseptic Prostatitis: Advancing Treatment Options

Chronic Aseptic Prostatitis, also known as chronic pelvic pain syndrome, presents significant challenges regarding effective treatment options. This condition, characterized by persistent pelvic pain and discomfort, requires ongoing research efforts to explore new avenues for managing and alleviating its symptoms. Prostamax, is a product currently under investigation. It shows promise as a potential solution for individuals suffering from Chronic Aseptic Prostatitis.

Prostamax is undergoing research and development to address the underlying causes of chronic pelvic pain and associated inflammation. Through comprehensive clinical trials and scientific investigations, researchers are working towards understanding the potential benefits of Prostamax in managing Chronic Aseptic Prostatitis.

The specific mechanisms of action and ingredients of Prostamax are being studied to assess their efficacy in reducing inflammation, alleviating pelvic pain, improving urinary symptoms, and enhancing overall prostate health. This research is crucial for determining the safety and effectiveness of Prostamax as a viable treatment option for individuals with Chronic Aseptic Prostatitis.

By investing in research on Prostamax, scientists aim to advance the understanding of the condition and expand the range of therapeutic options available. This research-driven approach promises to improve the quality of life for those affected by Chronic Aseptic Prostatitis, offering hope for effective management and long-term relief.

It is important to note that Prostamax is currently in the research and development stage.

With research treatments like Prostamax have the potential to revolutionize the management of Chronic Aseptic Prostatitis. Ultimately, offering hope for those living with this challenging condition.


Posted on

Buy ARA-290 Peptide | Explore the Potential of ARA-290 Benefits

Buy ARA-290 PeptideIf you want to buy ARA-290 peptide, one research company stands out as a reliable and reputable source Peptide Sciences. Peptide Sciences offers a compelling choice for obtaining this groundbreaking research peptide.
Their stringent quality control measures ensure that you receive a product of the highest purity and potency, meeting the rigorous standards of scientific research. With a track record of excellence to scientific advancement, Peptide Sciences is the go-to supplier for researchers seeking ARA-290 peptides. By choosing Peptide Sciences, you can have confidence in the integrity and reliability of the product, enabling you to conduct your research with precision and accuracy. Keep quality high in your scientific endeavors – trust Peptide Sciences to provide you with the ARA-290 peptide for sale for your cutting-edge studies.

What is ARA-290 Peptide?

ARA-290 is a research peptide currently under investigation. It has potential therapeutic benefits in various health conditions. The peptide has demonstrated promising results in improving cholesterol levels, wound healing, and pain management. As scientists delve deeper into understanding the mechanisms and potential applications of ARA-290, it holds promise as a groundbreaking treatment option.

In this article, we will explore the current state of research surrounding ARA-290 and its potential implications for human health.

ARA-290 has emerged due to extensive research focused on harnessing the therapeutic potential of peptides. Peptides are short chains of amino acids that play crucial roles in cellular signaling and various physiological processes. These molecules have garnered attention as potential candidates for targeted therapies due to their high specificity and low toxicity.


A Guide to ARA-290 Benefits From Studies

One of the notable areas where ARA-290 has shown promising effects is in the regulation of cholesterol levels. High cholesterol levels are a significant risk factor for cardiovascular diseases like heart attacks and strokes. Preliminary studies involving ARA-290 have revealed its ability to effectively modulate cholesterol metabolism, potentially leading to improved lipid profiles and reduced risk of cardiovascular complications. These findings highlight the potential of ARA-290 as a novel therapeutic approach to managing hypercholesterolemia and related conditions.

Another intriguing aspect of ARA-290’s potential lies in its impact on wound healing. Wound healing is a complex process involving inflammation, cell migration, and tissue regeneration. Impaired wound healing is a considerable medical challenge, particularly in chronic wounds or conditions such as diabetes. Research studies utilizing ARA-290 have shown promising results in enhancing the healing process by promoting cell proliferation, reducing inflammation, and stimulating angiogenesis. These findings suggest that ARA-290 could offer a revolutionary approach to facilitate the healing of chronic wounds and improve patient outcomes.

<<Buy ARA-290 Peptide For Research Only at the Best Prices>>

Furthermore, ARA-290 has exhibited the potential to control pain, a prevalent and debilitating symptom in numerous medical conditions. Chronic pain, whether neuropathic or inflammatory, often poses significant challenges in managing and quality of life for affected individuals. Studies investigating ARA-290’s analgesic properties have demonstrated its ability to modulate pain perception and attenuate acute and chronic pain states. This discovery opens up new possibilities for developing targeted pain management strategies that offer improved efficacy and reduced side effects compared to existing treatments.

What is the Mechanism of Action of Ara 290?

The mechanism of action of ARA-290, involves its interaction with specific receptors in the body. ARA-290 primarily targets the innate repair receptor (IRR), expressed on various cells, including immune and nerve cells. Upon binding to the IRR, ARA-290 activates intracellular signaling pathways crucial in regulating inflammatory responses, tissue repair, and pain modulation.

One key aspect of ARA-290’s mechanism of action is its ability to suppress excessive inflammation. An inflammatory response is triggered as a protective mechanism when the body encounters tissue damage or injury. However, in certain conditions, such as chronic inflammation or autoimmune disorders, this response can become dysregulated and contribute to tissue damage. ARA-290 acts as an anti-inflammatory agent by inhibiting the production and release of pro-inflammatory molecules, thereby helping to rescore the immune response balance.


ARA-290 also affects wound healing by promoting cellular proliferation, migration, and tissue regeneration. It enhances the production of growth factors and cytokines involved in these processes, thereby accelerating the healing of wounds. Additionally, ARA-290 stimulates the formation of new blood vessels (angiogenesis), crucial for supplying oxygen and nutrients to healing tissues.

Furthermore, ARA-290 has analgesic properties that can help control pain. It interacts with specific receptors in the nervous system, leading to the modulation of pain signaling pathways. By reducing the transmission of pain signals and inhibiting the release of pain-inducing substances, ARA-290 can relieve acute and chronic pain conditions.

Overall, the mechanism of action of ARA-290 involves:

  • Its interaction with the innate repair receptor.
  • Leading to anti-inflammatory effects.
  • Promotion of wound healing.
  • Pain modulation.

By targeting these pathways, ARA-290 shows potential as a therapeutic agent for various conditions where inflammation, impaired healing, and pain are significant factors.

What is Ara 290 Used For?

ARA-290, a research peptide currently under investigation, is being studied for its potential therapeutic applications in various health conditions. It is still in the early research stage and not approved for clinical use; preliminary studies suggest several possible benefits for ARA-290. Some of the areas where ARA-290 is being explored include:

  1. Hypercholesterolemia: ARA-290 has shown promising effects in improving cholesterol levels and lipid profiles. It might be a potential treatment option for managing elevated cholesterol levels and reducing the risk of cardiovascular diseases.
  2. Wound Healing: ARA-290 has exhibited properties that promote wound healing. It may help with the recovery of chronic wounds, such as diabetic ulcers, by stimulating cellular proliferation, reducing inflammation, and enhancing tissue regeneration.
  3. Pain Management: ARA-290 has shown potential in controlling pain. It has some analgesic effects in acute and chronic pain, including neuropathic and inflammatory pain. By modulating pain signaling pathways, ARA-290 may offer an alternative or adjunctive therapy for pain management.

Buy ARA-290 Peptide for Research Only

In conclusion, the ongoing research on ARA-290 has shed light on its potential therapeutic benefits in improving cholesterol levels, facilitating wound healing, and controlling pain. While these preliminary findings are encouraging, further investigations are necessary to fully understand the mechanisms of action and determine the safety and efficacy of ARA-290 in various patient populations. The continued exploration of this research peptide holds immense promise for developing innovative treatment options that could revolutionize healthcare and improve patient outcomes.

What is Small Fiber Peripheral Neuropathy?

Small fiber peripheral neuropathy (SFPN) is a peripheral neuropathy that primarily affects the tiny nerve fibers in the peripheral nervous system. The peripheral nervous system is where nerves stretch from the brain and spinal cord to other body parts, controlling sensation and movement.

In SFPN, the tiny nerve fibers that transmit sensory information, such as pain, touch, and temperature, become damaged or dysfunctional. It results in various symptoms, including:

  1. Sensory disturbances: Patients may experience unusual sensations such as tingling, burning, or numbness in the affected areas. These symptoms often start in the feet or hands and may gradually spread to other body parts.
  2. Pain: SFPN is commonly associated with chronic pain. The pain can be aching, stabbing, or shooting and may be present in a symmetric pattern.
  3. Autonomic dysfunction: Small nerve fibers also regulate autonomic functions, such as sweating, blood pressure, and digestion. Damage to these fibers can lead to excessive sweating, intolerance to heat or cold, dry eyes or mouth, gastrointestinal problems, and abnormal heart rate or blood pressure.

The causes of small fiber peripheral neuropathy can vary and may include:

  1. Diabetes: SFPN links to diabetes, especially in individuals with poor blood sugar control.
  2. Autoimmune disorders: Conditions like Sjögren’s syndrome, lupus, or rheumatoid arthritis can contribute to nerve damage.
  3. Infections: These can be viral or bacterial infections, such as HIV, Lyme disease, or hepatitis C, which can trigger SFPN.
  4. Toxins: Exposure to certain toxins, such as chemotherapy drugs, industrial chemicals, or heavy metals, may cause small fiber neuropathy.
  5. Idiopathic: In some cases, the cause of SFPN remains unknown.

Diagnosing small fiber peripheral neuropathy typically involves a combination of medical history evaluation, physical examination, nerve conduction tests, and skin biopsies to assess the density of small nerve fibers. Treatment aims to manage symptoms and address any underlying causes. Medications for pain management, lifestyle modifications, physical therapy, and addressing underlying conditions are some strategies employed.

It’s essential to consult a healthcare professional for an accurate diagnosis and appropriate management of small fiber peripheral neuropathy.

Is Ara 290 for the Treatment of Small Fiber Neuropathy in Sarcoidosis?

Ara 290 is a peptide developed by Araim Pharmaceuticals. It has shown potential therapeutic effects in various inflammatory and autoimmune conditions, including sarcoidosis.  

Ara 290 for treating small fiber neuropathy, specifically in sarcoidosis, had not been extensively studied or approved by regulatory authorities. However, some preclinical and early clinical studies have shown promising results in the context of neuropathic pain associated with other conditions.

What is Sarcoidosis and Treatment?

Sarcoidosis is a complex disease characterized by forming granulomas (inflammatory nodules) in various organs, including the lungs, skin, eyes, and nerves. Small fiber neuropathy is one of the neurological manifestations that can occur in sarcoidosis, leading to symptoms such as pain, numbness, and sensory disturbances.

The primary treatment approach for sarcoidosis-related small fiber neuropathy involves managing the underlying sarcoidosis itself. It may include systemic corticosteroids or other immunosuppressive medications to reduce inflammation and control the disease. Additionally, the management of neuropathic pain can be from medications such as tricyclic antidepressants, antiepileptic drugs, or other pain medications.

Suppose you or someone you know is affected by small fiber neuropathy in the context of sarcoidosis. In that case, consult a healthcare professional specializing in managing sarcoidosis or neuropathic conditions. They can provide the most up-to-date information on available treatment options.

<<Best Place to Buy ARA-290 Peptide Order Now>>

Posted on

Cerebrolysin Benefits | Buy Cerebrolysin

Cerebrolysin BenefitsCerebrolysin is a research peptide that is derived from porcine brain tissue and is composed of a mixture of low molecular weight peptides and amino acids. The drug has been studied for its potential neuroprotective and cognitive-enhancing effects, and it has shown promise in preclinical studies.

<< Buy Cerebrolysin for Research Use Only>>

In animal studies, Cerebrolysin has been shown to improve cognitive function and memory retention, increase synaptic plasticity, and reduce neuronal damage caused by neurodegenerative diseases. The drug has also been found to have neuroprotective effects in models of stroke, traumatic brain injury, and spinal cord injury.

While Cerebrolysin has not yet been approved for clinical use in humans, researchers continue to study the drug for its potential therapeutic benefits. Some studies have suggested that Cerebrolysin may be effective in treating conditions such as Alzheimer’s disease, Parkinson’s disease, and stroke.

<<Cerebrolysin For Sale at the Best Prices Online>>

In Alzheimer’s disease, Cerebrolysin has been shown to improve cognitive function and reduce the progression of the disease in animal models. In Parkinson’s disease, the drug has been found to improve motor function and reduce the loss of dopaminergic neurons. And in stroke, Cerebrolysin has been shown to reduce the size of the infarct and improve functional recovery.

Despite the promising results from preclinical studies, it is important to note that Cerebrolysin is not approved for clinical use in humans. The drug should only be used by qualified researchers who are conducting studies on its safety and efficacy.

What is Cerebrolysin Used For?

Cerebrolysin is a medication used for the treatment of various neurological conditions. It is a peptide-based nootropic drug derived from porcine brain proteins, which has been shown to have neuroprotective, neuroregenerative, and cognitive enhancing effects.

The research peptide Cerebrolysin is commonly used in the treatment of Alzheimer’s disease, dementia, stroke, traumatic brain injury, and other neurological disorders. It is believed to work by promoting the growth and repair of brain cells, improving blood flow to the brain, and enhancing the functioning of neurotransmitters.

What Does Cerebrolysin Do to the Brain?

Cerebrolysin benefits brain health including neuroprotection, neuroregeneration, and cognitive enhancement.

Neuroprotection refers to the ability of Cerebrolysin to protect the brain cells from damage or degeneration caused by various factors such as aging, toxins, and diseases. It does this by reducing oxidative stress, inflammation, and apoptosis, which are all known to contribute to neurodegeneration.

Neuroregeneration refers to the ability of Cerebrolysin to stimulate the growth and repair of brain cells. It can promote the formation of new neurons and synapses, which can improve the overall structure and function of the brain.

Cerebrolysin also has cognitive enhancing effects. It means it can improve various aspects of cognitive function, such as memory, attention, and learning. Cerebrolysin increases the levels of neurotransmitters such as acetylcholine and dopamine, which are essential for cognitive processes.

Overall, Cerebrolysin can improve the health and functioning of the brain. It can protect from damage, promoting its growth and repair, and enhancing cognitive function.

Is Cerebrolysin Legal?

Cerebrolysin is a legal medication that is available by prescription in many countries. It has been used for several decades in Europe, Asia, and other parts of the world for the treatment of various neurological conditions. However, in the United States, Cerebrolysin is not approved by the Food and Drug Administration (FDA) for use as a medication. It is a research peptide for study use only.


What Type of Drug is Cerebrolysin?

Cerebrolysin is a nootropic drug that is derived from porcine brain proteins. It is classified as a peptide-based drug, which means it is composed of a chain of amino acids that are linked together.

Cerebrolysin is believed to have neuroprotective, neuroregenerative, and cognitive enhancing effects, which make it useful in the treatment of various neurological conditions. It is often used to improve cognitive function and memory in patients with Alzheimer’s disease, dementia, and other cognitive disorders.

Cerebrolysin is administered through injection and is available by prescription in many countries. It is important to note that the regulatory status of Cerebrolysin can vary depending on the country and region. It is always best to consult with a healthcare professional or regulatory authority in your area to determine the appropriate use and legality of Cerebrolysin.

What is Cerebrolysin Good For?

Cerebrolysin is a medication that is used to treat various neurological conditions. It is commonly used for the following purposes:

  1. Alzheimer’s disease: Cerebrolysin has been shown to improve cognitive function and memory in patients with Alzheimer’s disease, which is a type of dementia that affects memory, thinking, and behavior.
  2. Dementia: Cerebrolysin may also be beneficial in the treatment of other types of dementia, such as vascular dementia and Lewy body dementia. It can improve cognitive function and slow down the progression of the disease.
  3. Stroke: Cerebrolysin can be used to improve the outcomes of patients who have had a stroke. It can help to reduce brain damage and promote the repair and regeneration of brain cells.
  4. Traumatic brain injury: Cerebrolysin can be used to improve the outcomes of patients who have suffered from traumatic brain injury. It can reduce inflammation, promote the repair of brain cells, and improve cognitive function.
  5. Cognitive enhancement: Cerebrolysin may also be used as a cognitive enhancer to improve memory, attention, and other cognitive processes in healthy individuals.

Overall, Cerebrolysin has neuroprotective, neuroregenerative, and cognitive enhancing effects that make it useful in the treatment of various neurological conditions.

Does Cerebrolysin Improve Memory?

Cerebrolysin has been shown to improve memory in some patients. Cerebrolysin is a nootropic drug that has been found to have cognitive enhancing effects, including improving memory. It is believed to work by promoting the growth and repair of brain cells, improving blood flow to the brain, and enhancing the functioning of neurotransmitters such as acetylcholine, which is essential for memory processes.

Studies have shown that Cerebrolysin can improve memory in patients with Alzheimer’s disease and other forms of dementia. It can also improve memory in healthy individuals who are experiencing age-related memory decline or cognitive impairment. However, it is important to note that the effectiveness of Cerebrolysin can vary depending on the individual and the specific condition being treated.

A Summary | Cerebrolysin Review

Cerebrolysin has been extensively studied in various research studies, particularly in Europe and Asia. Many of these studies have shown promising results, particularly in the treatment of Alzheimer’s disease, dementia, stroke, and traumatic brain injury.

One meta-analysis published in 2017 reviewed 10 randomized controlled trials that investigated the use of Cerebrolysin in patients with Alzheimer’s disease. The study found that Cerebrolysin significantly improved cognitive function, particularly in areas such as memory and attention, and that it was generally well-tolerated by patients.

Another meta-analysis published in 2015 reviewed 11 studies that investigated the use of Cerebrolysin in stroke patients. The study found that Cerebrolysin improved functional outcomes, such as activities of daily living and motor function, in patients who received the medication.

Additionally, several studies have investigated the use of Cerebrolysin in traumatic brain injury patients, and have found that it may improve cognitive function and reduce inflammation in the brain.

Overall, while more research is needed to fully understand the potential benefits and risks of Cerebrolysin, many studies have shown promising results. It is important to note that Cerebrolysin should only be used under the guidance of a healthcare professional and in accordance with its approved use.

Where to Buy Cerebrolysin?

Peptide Sciences is a well-established research company that provides a wide range of peptides, including Cerebrolysin. They have a reputation for providing high-quality peptides that meet the needs of researchers, and they use advanced technologies to ensure the purity and accuracy of their products.

Cerebrolysin, on the other hand, is a neuropeptide that has been extensively studied for its potential therapeutic benefits in various neurological conditions. It has neuroprotective, neuroregenerative, and cognitive-enhancing effects that make it a promising drug for treating conditions such as Alzheimer’s disease, stroke, and traumatic brain injury.

Peptide Sciences offers Cerebrolysin for research purposes only, and it is important to note that it is not approved for human use in the United States. Researchers who wish to purchase Cerebrolysin from Peptide Sciences should ensure that they are using it in accordance with all applicable regulations and guidelines.

Overall, while Peptide Sciences is a well-established research company that provides high-quality peptides, researchers should carefully consider their research needs and consult with a healthcare professional or regulatory agency to ensure that they are using Cerebrolysin safely and effectively.

Conclusion Cerebrolysin Benefits

In conclusion, Cerebrolysin is a research peptide that has shown promise in preclinical studies for its potential neuroprotective and cognitive-enhancing effects. While the drug is not currently approved for clinical use in humans, researchers continue to study its potential therapeutic benefits in a range of neurological conditions.

Posted on

Unlocking the Truth Behind Liraglutide Weight Loss Reviews

 Liraglutide Weight Loss ReviewsLiraglutide Weight Loss Reviews: Liraglutide is a medication approved by the FDA for the treatment of type 2 diabetes and obesity. It belongs to a class of drugs called glucagon-like peptide-1 (GLP-1) receptor agonists. These drugs mimic the effects of the hormone GLP-1, which is naturally produced in the body to regulate blood sugar levels and appetite.

Studies have shown that liraglutide can lead to significant weight loss in obese individuals. In a clinical trial involving overweight and obese individuals with type 2 diabetes, those who received liraglutide lost an average of 6% of their body weight over a 56-week period, compared to 2% in the placebo group.

Another study showed that liraglutide can also improve cardiovascular health. In a clinical trial involving overweight and obese individuals with high cardiovascular risk, those who received liraglutide had a lower incidence of major cardiovascular events compared to those who received a placebo.


Liraglutide works by increasing feelings of fullness and reducing appetite, leading to a reduction in calorie intake. It also slows down the emptying of the stomach, which can lead to a longer feeling of fullness and satiety.

However, like any medication, liraglutide has potential side effects, including nausea, vomiting, diarrhea, and pancreatitis. It is important to speak with a healthcare provider to determine if liraglutide is a suitable treatment option for an individual’s weight loss goals and overall health.

How Much Weight Can You Lose in a Month with Liraglutide?

From studies, the amount of weight an individual can lose with Liraglutide may vary based on various factors such as age, gender, starting weight, and lifestyle habits. However, clinical trials have shown that individuals who took Liraglutide for weight loss lost an average of 4-6% of their body weight after 16-20 weeks of treatment.

This means that for an individual who weighs 200 pounds, they could potentially lose 8-12 pounds in 4 months (16 weeks) to 10-12 pounds in 5 months (20 weeks) while taking Liraglutide, when combined with diet and exercise.

It is important to note that weight loss is not guaranteed, and results may vary for each individual. Also, Liraglutide should only be taken under the supervision of a healthcare professional, who can monitor its effectiveness and potential side effects.

How Long Does it Take for Liraglutide to Work for Weight Loss?

Liraglutide is not a quick fix for weight loss and it may take several weeks to see noticeable results. Clinical trials have shown that individuals taking Liraglutide for weight loss typically begin to see weight loss results within the first 4-6 weeks of treatment. However, the full weight loss potential may take up to 20 weeks or longer to achieve.

It is important to note that Liraglutide should be used in conjunction with a healthy diet and exercise regimen for optimal weight loss results. Additionally, individual results may vary, and it is important to follow the guidance of a healthcare professional when taking Liraglutide for weight loss.


How Much Weight Can I Lose in a Month with Saxenda?

Saxenda is a brand name medication that contains the active ingredient liraglutide and is approved by the FDA for weight loss. The amount of weight an individual can lose with Saxenda may vary based on various factors such as age, gender, starting weight, and lifestyle habits.

In clinical trials, individuals who took Saxenda for weight loss lost an average of 4-6% of their body weight after 16-20 weeks of treatment. This means that for an individual who weighs 200 pounds, they could potentially lose 8-12 pounds in 4 months (16 weeks) to 10-12 pounds in 5 months (20 weeks) while taking Saxenda, when combined with diet and exercise.

It is important to note that weight loss is not guaranteed, and results may vary for each individual. Additionally, Saxenda should only be taken under the supervision of a healthcare professional, who can monitor its effectiveness and potential side effects.

Is Liraglutide Effective for Weight Loss?

Yes, liraglutide has been shown to be effective for weight loss in clinical trials. Liraglutide belongs to a class of drugs called GLP-1 receptor agonists, which work by increasing feelings of fullness and reducing appetite, leading to a reduction in calorie intake. It also slows down the emptying of the stomach, which can lead to a longer feeling of fullness and satiety.

In clinical trials, individuals who took liraglutide for weight loss lost an average of 4-6% of their body weight after 16-20 weeks of treatment, compared to 1-2% in the placebo group. Additionally, liraglutide has been shown to have other health benefits, such as improving cardiovascular health.

However, it is important to note that liraglutide should only be taken under the supervision of a healthcare professional, who can monitor its effectiveness and potential side effects. Additionally, weight loss results may vary for each individual and should be combined with a healthy diet and exercise regimen for optimal results.


Saxenda Weight Loss Reviews

Ben: “Saxenda has changed my life! I’ve been struggling with weight loss for years and tried everything from fad diets to intense workout regimens. Nothing seemed to work until I started taking Saxenda. With the help of my healthcare provider and a healthy diet and exercise routine, I’ve lost 15 pounds in just three months. I feel more energized and confident than ever before. Highly recommend giving Saxenda a try!”

Sally: “I was skeptical about trying Saxenda for weight loss, but I’m glad I did. It’s been two months, and I’ve already lost 8 pounds. It’s definitely not a magic pill, and I still have to put in the effort to eat healthy and exercise regularly. However, Saxenda has helped curb my appetite and make it easier to stick to my weight loss goals. The only downside is the cost, but my insurance covers it, so it’s worth it for me.”

Zak: “I’ve been taking Saxenda for six months now and have lost a total of 20 pounds. It’s been a slow and steady journey, but Saxenda has been a great tool for weight loss. The injection can be a bit painful, but I’ve gotten used to it over time. The biggest challenge has been sticking to a healthy diet and exercise routine, but Saxenda has helped make it easier. I definitely recommend Saxenda to anyone looking for a weight loss aid.”

Sienna: “I had a lot of reservations about taking Saxenda, especially after reading about the potential side effects. However, I talked to my healthcare provider and decided to give it a try. Unfortunately, I didn’t have a great experience with Saxenda. I experienced nausea and vomiting, and it didn’t seem to help with my appetite. I stopped taking it after a month because the side effects weren’t worth it for me. It’s important to talk to your doctor about the potential risks and benefits before starting Saxenda.”

Liraglutide for Weight Loss in Non Diabetics

Liraglutide has been approved by the FDA for weight loss in non-diabetics who have a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related condition such as high blood pressure, type 2 diabetes, or high cholesterol.

In clinical trials, liraglutide has been shown to be effective for weight loss in non-diabetics. In one study, non-diabetic individuals who took liraglutide lost an average of 8% of their body weight after 56 weeks of treatment, compared to 2.6% in the placebo group.

Liraglutide works by slowing down the emptying of the stomach, which can lead to a longer feeling of fullness and satiety. It also increases feelings of fullness and reduces appetite, leading to a reduction in calorie intake.

However, it is important to note that liraglutide should only be taken under the supervision of a healthcare professional, who can monitor its effectiveness and potential side effects. Additionally, weight loss results may vary for each individual and should be combined with a healthy diet and exercise regimen for optimal results.

What are Liraglutide Weight Loss Side Effects

Liraglutide is generally well-tolerated, but like all medications, it can cause side effects in some people. The most common side effects associated with liraglutide for weight loss include:

  1. Nausea: This is the most common side effect and may occur in up to 40% of people who take liraglutide. It usually subsides over time as the body adjusts to the medication.
  2. Diarrhea: This is another common side effect and can occur in up to 25% of people who take liraglutide. It may also subside over time.
  3. Vomiting: Some people may experience vomiting when taking liraglutide.
  4. Constipation: This side effect is less common than diarrhea and may occur in up to 10% of people who take liraglutide.
  5. Headache: Headaches are a common side effect of many medications, and liraglutide is no exception.
  6. Low blood sugar: Liraglutide can lower blood sugar levels, especially in people with type 2 diabetes who are taking other blood sugar-lowering medications.
  7. Gallbladder problems: Liraglutide has been associated with an increased risk of gallbladder problems, including gallstones.
  8. Pancreatitis: In rare cases, liraglutide can cause inflammation of the pancreas, a serious condition known as pancreatitis.

What is Victoza Weight Loss Dosage?

Victoza (liraglutide) is a medication approved by the FDA for the treatment of type 2 diabetes. It is also used off-label for weight loss, as it has been shown to be effective in reducing body weight in overweight and obese individuals.

The recommended dose for Victoza for weight loss is 3 mg once daily, injected subcutaneously (under the skin) in the abdomen, thigh or upper arm. It should be taken at any time of the day, with or without food. However, the dose and duration of treatment may vary based on individual response and tolerability.

Victoza works by mimicking the action of a hormone called glucagon-like peptide-1 (GLP-1), which is produced by the intestines. GLP-1 helps to regulate blood sugar levels by stimulating insulin release, suppressing glucagon secretion, and slowing down the emptying of the stomach. This leads to a longer feeling of fullness and satiety, which can result in a reduction in calorie intake and weight loss.

Victoza also has an effect on the brain, specifically on the hypothalamus, which is responsible for regulating appetite and energy balance. By acting on these areas of the brain, Victoza can reduce cravings and appetite, leading to further weight loss.

It is important to note that Victoza should only be used for weight loss under the supervision of a healthcare provider, who can monitor for potential side effects and adjust the dose as needed. It should not be used by individuals with a history of pancreatitis or thyroid cancer, or by those who have a personal or family history of medullary thyroid cancer.

The amount of weight loss that can be achieved with Victoza (liraglutide) varies depending on individual factors such as starting weight, diet, and exercise habits. However, clinical studies have shown that Victoza can lead to significant weight loss in overweight and obese individuals.

In a 56-week clinical trial of liraglutide for weight management, participants who took Victoza lost an average of 6% of their body weight compared to 2% for those taking a placebo (inactive treatment). This translates to an average weight loss of approximately 12 pounds for those starting at 200 pounds.

Another study showed that participants who took Victoza at a dose of 3 mg per day lost an average of 5.5% of their body weight after 32 weeks, compared to 1.5% for those taking a placebo.

It is important to note that weight loss results may vary depending on individual response and adherence to the medication, as well as lifestyle factors such as diet and exercise. Victoza is most effective when used as part of a comprehensive weight loss plan that includes a healthy diet and regular exercise.

It is also important to talk to your healthcare provider about the potential risks and benefits of Victoza for weight loss, as well as to report any side effects you experience while taking the medication.

Where to Buy – Liraglutide Weight Loss Reviews

Liraglutide is a prescription medication that is typically used to treat type 2 diabetes. However, it has also been shown to be effective for weight loss in overweight and obese individuals. If you are interested in trying liraglutide for weight loss, it is important to know where to buy it and to make sure that you are purchasing it from a reputable source.

One option for purchasing liraglutide for weight loss is through online peptide retailers such as Peptides USA Peptides USA is a website that offers a variety of research peptides, including liraglutide. The website is a popular choice for individuals who are looking for high-quality peptides at affordable prices.

Buy  liraglutide from Peptides USA it is important to do your research and make sure that the website is legitimate and trustworthy. You can check for customer reviews and ratings, as well as the website’s overall reputation and customer service record. Additionally, it is recommended to only purchase liraglutide with a prescription from a licensed healthcare provider.

It is important to note that liraglutide is a prescription medication, and it should only be used under the supervision of a healthcare provider. It is also important to follow the recommended dosage and usage instructions to minimize the risk of side effects and ensure maximum effectiveness.

In conclusion, if you are interested in purchasing liraglutide for weight loss, it is recommended to consult with a licensed healthcare provider and to purchase it from a reputable source such as Peptides USA. It is also important to follow proper usage and dosage instructions to ensure safe and effective use of the medication.



Posted on

Diabetes Research: Groundbreaking

Diabetes ResearchDiabetes Research is Groundbreaking!

American Diabetes Association Congress: Individualization at All Levels of Therapy

Patients should set glycemic targets based on individual characteristics and priorities as diabetes progresses.

New data and studies commentators say are “groundbreaking.”

The American Diabetes Association 2021 (ADA) Virtual Convention offered much. The target group were not only diabetologists but also care of people with type 2 diabetes.

Personalized therapy goals for patients with type 1 diabetes

To date, national and international guidelines on type 1 diabetes are only based on evidence derived from type 2 studies. “Of course, we have guidelines for the management of people with type 1 diabetes, but this is mostly mixed up with broader recommendations that focus on type 2 diabetes,” stated Anne L. Peters, Keck School of Medicine, Los Angeles.

European and American diabetes societies have now joined forces to finally develop their “own” evidence-based recommendations for type 1 diabetes. The final version was presented at the EASD Congress at the end of September (see article below). There was already a foretaste at the ADA Congress.

What is the latest research on diabetes?

Individualization is the keyword at all levels. Diabetes starts with the glycemic target values. It should be set for each patient according to individual characteristics and priorities. But it can change as the disease progresses. HbA1c remains a vital parameter; and is complemented by other metrics such as pre-and postprandial blood glucose, time in range and glycemic variability. For most patients, an HbA1c target below 7% is adequate. “But any reduction in HbA1c is beneficial, even if the target cannot be reached,” emphasized Peters.

Insulin therapy should mimic the physiological situation as best as possible and allow those affected a high degree of flexibility in everyday life, including concerning nutrition and physical activity, explained Sue Kirkman, University of Chicago. The consensus report recommends insulin pumps or multiple daily injections, preferably with insulin analogues. Continuous glucose monitoring and closed-loop systems are rated even better, but they are unavailable everywhere and cause significantly higher costs.

With a separate chapter, the report acknowledges the high psychosocial and mental stress that type 1 diabetes poses to those affected, reported Frank J. Snoek, University of Amsterdam. “Emotional health is an important outcome of diabetes therapy, and it requires a personal approach,” says the medical psychologist.

To support people with type 1 diabetes, physicians should specifically develop their professional skills to talk about problems with self-management and coping with emotional and social burdens.

Diabetic Nephropathy: KDIGO gives detailed recommendations

EASD and ADA address diabetic nephropathy as part of their recommendations for managing type 2 diabetes.

KDIGO (Kidney Disease: Improving Global Outcomes) has devoted its 120-page guideline to it — Almost anyway, because according to the focus of the international organization, the topic is not “kidney damage in diabetes” but “diabetes management in chronic kidney disease”. 

Diabetes ResearchThe KDIGO makes no distinction between type 1 and types 2 diabetes.

The guidelines agree on many core aspects, emphasized John B. Buse, University of North Carolina, Chapel Hill. The standard is that people with diabetic kidney damage should receive a RAS inhibitor, especially if they also have hypertension, as is often the case. The dose should be up to the maximum, and the blood pressure should be lowered to at least below 140/90 mmHg — if the patient can tolerate it, it can be lower. According to KDIGO, an increase in creatinine under RAS inhibitor therapy can be tolerated if it does not exceed 30% in 4 weeks and there is no volume depletion.

Is There Diabetes Research?

Irrespective of the initial and current HbA1c value, antihyperglycemic pharmacotherapy now includes an SGLT2 inhibitor. It is an indispensable partner in addition to metformin as long as the eGFR is at least 30 ml/min. 

According to the unanimous opinion of the guideline authors, the best evidence of nephroprotection exists for gliflozine. Buse pointed out that the eGFR can drop at the beginning of therapy.

However, this is no reason to discontinue the SGLT2 inhibitor, as kidney performance stabilizes over the long term. If the patient does not tolerate the SGLT2 inhibitor or if there are contraindications, a GLP1 receptor agonist should preferably be prescribed for further blood sugar reduction. In the case of SGLT2 inhibitors such as GLP1-RA, active substances should be chosen whose cardio-renal benefit has been demonstrated in high-quality endpoint studies.

Top Antidiabetics in a head-to-head Comparison

Metformin was in place as first-line therapy, but it was unclear which antidiabetic would be best for second-line. It looked like when GRADE (Glycemia Reduction Approaches in Diabetes) was conceived in 2009 and launched in 2013. The industry-independent head-to-head study could serve as a model for a realistic study design. Unfortunately, the reality was not the case.

Is Triple Therapy the Optimum for Type 2 Diabetes?

According to Ralph A. DeFronzo, the University of Texas at San Antonio, there is a clear answer to the best therapy for type 2 diabetes.

-The triple combination of SGLT2 inhibitor, GLP-1 receptor antagonist (GLP1 RA) and pioglitazone

-No single antidiabetic has been able to combat all of the metabolic disorders that underlie type 2 diabetes

-The three active substances/active substance classes mentioned intervene in practically all central mechanisms of diabetes pathogenesis, explained De Fronzo.

How Likely is a Cure for Diabetes?

SGLT2 inhibitors slow down the increased glucose reabsorption in the kidney, improve beta cell function and increase glucose uptake in the muscles. 

GLP1-RAs complement this by increasing insulin secretion, slowing down glucagon secretion and exerting beneficial effects on liver and neurotransmitter function — key words: appetite and satiety. 

Thiazolidinediones such as pioglitazone are the only actual insulin sensitizers. Still, they have fallen into disrepute because of weight gain, especially since the positive effects on beta cell function, insulin sensitivity and HbA1c are more significant the more the patient gains weight. The triple combination with SGLT2 inhibitor and GLP1-RA can counterbalance the weight effect of pioglitazone. It does this without counteracting metabolic effects.

All three combination candidates reduce not only hyperglycemia-related microvascular complications but also provide cardiovascular protection, DeFronzo noted. 

The evidence for SGLT2 inhibitors and GLP1-RA is more solid than for pioglitazone, for which there are no studies with cardiovascular complications as the primary endpoint.

SGLT2 inhibitors reduce the risk- presumably primarily via haemodynamic effects — in addition to the known weight and blood pressure effects—the reduction in sympathetic tone and the increased availability of ketones as an energy source in the myocardium. 

In addition to reducing weight, blood pressure and lipids, GLP1-RA also has an anti-atherogenic, anti-inflammatory and anti-thrombotic effect. 

GLP-1 receptors are also found in the human heart, making direct myocardial effects likely, although what they look like is not entirely clear. Pioglitazone combines beneficial effects on inflammation, lipotoxicity, blood pressure and lipid profile.

Twincretin-based against diabetes and obesity

Stimulating two incretin receptors is likely to have a more substantial effect than a single agonist. It is the idea behind developing the GIP/GLP-1 receptor agonist Tirzepatide. 

In the phase 3 program SURPASS has demonstrated potent antidiabetic and weight-loss effects without increasing the risk of hypoglycemia.

The two incretins GLP-1 and GIP overlap and complement each other in their effects on the pancreas, gastrointestinal tract, adipose tissue and CNS, explained Daniel Drucker, University of Toronto. 

Tirzepatide can bind to the GLP1 and GIP receptors, providing a dual effect with a single molecule. One subcutaneous injection is enough for a week. The SURPASS program includes ten studies, 4 of which were presented at the ADA Congress. All showed an hba1c solid reduction of 2–2.5% and a drastic weight loss of about 12 kg within 40–52 weeks, as well as the usual incretin-associated gastrointestinal side effects with no significant surprises

The 40-week open-label study SURPASS-2, in which tirzepatide was compared with semaglutide, which has already been approved for the treatment of type 2 diabetes and also obesity in the USA. It has aroused the most significant interest. The comparison was not entirely fair, as semaglutide is dosed higher in obesity therapy than in diabetes treatment and in SURPASS-2 (2.4 mg/week instead of 1 mg/week). At the start of the study, however, only the 1 mg dosage was approved in the USA, explained study leader Juan Pablo Frías, National Research Institute, Los Angeles. One thousand eight hundred seventy-nine people who were stable on at least 1,500 mg/day of metformin as background therapy were randomized.

Is there a true cure for diabetes?

In terms of HbA1c, the dual agonist performed significantly better than the GLP1-RA in all three doses tested (5, 10 and 15 mg/week) (minus 2.09%–2.46% vs. 1.86%, p<0.001 ). Tirzepatide is superior in the anti-obesity effect, with weight losses of up to 12.4 kg in the 15 mg/week arm (6.2 kg with Semaglutide, p<0.001). 

However, more patients discontinued in the two study arms with higher doses of tirzepatide than with semaglutide (12% and 13.2% vs 8.7%), primarily because of adverse effects.

For Drucker, these study results open “the next chapter in incretin-based therapies that will bring meaningful improvements in the health and quality of life of people with diabetes.” He was convinced that tolerability in everyday clinical practice would be better if doctors and patients could manage the dose flexibly.


Diabetes mellitus is associated with obesity and insulin resistance. Therefore, the therapy aims to lower the blood sugar level and reduce the patient’s body weight. Some active ingredients, thus, attack the so-called incretins. These postprandially released molecules regulate, among other things, how much glucagon and insulin release. Glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are two such molecules.

GLP-1 inhibits glucagon release, promotes insulin release, delays gastric emptying, and inhibits hunger and thirst. GIP also stimulates glucose-dependent insulin secretion. It regulates glucagon release both in a hyperglycaemic phase and in a normal- or hypoglycaemic state.

The receptor of the GLP-1 molecule has, therefore long been the target structure of the GLP-1 receptor agonists. Combination agents of GIP and GLP-1 receptor agonists are now being explored. One such is tirzepatide.

Disclaimer “To keep content unique, this article contains affiliate links connected to the topic to credit our writers.”


Posted on

Lung Cancer Summary

lung cancer summary
Buy Bronchogen Peptide

Lung Cancer Summary – Lung cancer is a malignant disease that is the most common cause of death from a neoplastic entity in men. Its frequency amounts to 25/100,000 people per year. The male: female ratio is 3:1 (except for adenocarcinoma, where this ratio is 6:1 in favor of females). The disease occurs between the ages of 55 and 60, but there are cases diagnosed before age 40.

What are Lung Cancer Causes?

As with all malignant diseases, the specific cause of malignant degeneration of cells is unknown. Many carcinogenic substances have a predisposing effect. In 85% of cases, inhalation of cigarette smoke is the cause of the development of bronchial carcinoma (which is one of the histological types of carcinoma). The risk increases as the duration and quantity of cigarettes smoked increase. Potentiation of risk is when smoking is combined with exposure to occupational carcinogens (e.g. asbestos). Even passive smoking can increase the risk of malignancy.

Several groups of carcinogenic chemicals are known:

-Chromium-6-compounds – especially zinc, strontium and calcium chromate
-Arsenic compounds – arsenic acid and its salts, arsenic trioxide, etc.
-Dichlorodiethylene sulfide
-Ionizing radiations – radon, uranium
-Asbestos – chrysotile, crocidolite, amosite, anthophyllite,
-Polycyclic aromatic hydrocarbons – benzopyrene, indenopyrene

Other risk factors are genetic predisposition and the presence of pulmonary scars.

What are the Disease Changes?

According to localization, lung cancer is split into:

-Central (perihilar) carcinoma – usually small cell or squamous cell
-Peripheral carcinoma – a particular form is a Pancoast-Tobias tumor – with peak localization
-Diffuse lung carcinoma

According to the histological structure, lung cancer divides into two main types:

Small cell carcinoma (SCLC – small cell lung cancer) – has mainly a central localization and is distinguished by the most unfavorable prognosis. In 80% of cases, the tumour has already metastasized when the diagnosis is made. Often, the cells look like oat cells under a microscope (oat cell carcinoma) and may secrete hormones.

Non-small cell lung cancer (NSCLC – non-small cell lung cancer). It, in turn, can be several options:

-Squamous cell carcinoma – mainly with central localization (most common type)
-Adenocarcinoma – often with peripheral localization and is the most common form of carcinoma in non-smokers
-Broncho-alveolar carcinoma – carcinoma of alveolar cells, which is also an adenocarcinoma
-Large cell lung carcinoma

The presence of a predisposition and the action of carcinogens leads to the appearance of the tumor. The following processes occur – metaplasia of the bronchial cylindrical epithelium into squamous, followed by epithelial dysplasia and carcinoma development. Through these “steps”, squamous cell bronchial carcinoma development passes. It is also the most common association to the greatest extent with smoking.

According to the degree of differentiation, the carcinoma divides into G1 (good), G2 (medium), G3 (poorly differentiated) and G4 (undifferentiated). It metastasizes to the regional lymph nodes. Hematogenous distant metastases are often already present at diagnosis in small cell carcinoma. Common localizations are the liver, skeleton, adrenal glands, and brain.

What are the Symptoms of Lung Cancer?

In the early stage, there are virtually no complaints. Some symptoms are Cough, shortness of breath, and chest pain. Hemoptysis may also be present, but it is more often a late manifestation of the disease. The appearance of asthma or chronic bronchitis at a late age and with a short history, treatment-resistant colds, and recurrent pneumonia requires increased attention. Late manifestations of the disease are a hoarse voice (paresis of the recurrent nerve) and a pleural effusion, especially of a hemorrhagic nature.

In the rare Pancoast tumor, which affects the apices of the lungs and involves the chest wall, the cervical part of the sympathetic and nerve roots are damaged. Ultimately this leads to bone destruction of the first rib and the first thoracic vertebra, arm pain (neuralgic pain from brachial plexus involvement), the Clode-Bernar-Horner triad – unilateral miosis, eyelid ptosis, and enophthalmos.

Broncho-alveolar carcinoma is often confused with chronic pneumonia. It presents a dry, irritating cough with mucus-watery expectoration and has a poor prognosis. It is inoperable due to its diffuse spread.

Small cell carcinoma can arise from cells of the APUD (Amine Precursor Uptake Decarboxylase) system. They have the property of secreting biologically active substances and hormones. Therefore, in small cell carcinoma, the so-called paraneoplastic syndromes and endocrinopathies:

Cushing’s syndrome – due to ectopic production of adrenocorticotropic hormone:

-Syndrome of inadequate secretion and antidiuretic hormone
-Tumor hypercalcemia due to the production of parathormone-like peptides
-Lamber-Eaton syndrome – weakness in the proximal musculature of the limbs, which leads, for example, to difficulty climbing stairs;
-Polymyositis and dermatomyositis
-Paraneoplastic tendency to thrombosis

On the x-ray examination, the picture of the appearance of the tumor can be the most diverse according to localization, shape, and stages.

The radiograph can give data on:

-obstructive emphysema
-atelectasis, abscessation
-a rounded focus with decay
-ring-shaped shadow
-necrotic round focus with a breakthrough to the pleural cavity
pleural effusion, etc.

Laboratory data usually show no abnormalities. Tumor markers can be tested, but they are not good at screening tests, only for therapeutic follow-up.

How is Lung Cancer Diagnosis Made?

The diagnosis is complex. Anamnestic data are often uncharacteristic. A guiding method for detecting the localization of the process is the chest X-ray. There is no form of lung shadowing that CAN NOT hide lung carcinoma. Therefore, computed axial tomography (CAT scanner) is suggested.

The diagnosis is confirmed by performing bronchoscopy and taking material for histological examination.
A diagnostic thoracotomy is performed if it is impossible to take material from tumor tissue during a bronchoscopic examination.

Diagnostic studies must be carried out to establish possible distant metastases – CT scan of the brain, echography or CT scan of abdominal organs, and bone scintigraphy.

The histological determination of the tumor and the determination of the spread of the process by imaging studies are the determining factors for the upcoming therapeutic interventions.

What Can go Wrong?

The symptoms and the chest x-ray resemble several lung diseases: pneumonia, acute and chronic bronchitis, pulmonary emphysema, COPD, bronchial asthma, upper respiratory tract infections, lung metastases from another primary focus, etc.
Treatment-resistant colds in people over 40 require all necessary diagnostic procedures to rule out lung carcinoma. Any cough that persists for more than four weeks despite treatment should be clarified.

What is the Main Lung Cancer Treatment?

Treatment includes surgery, radiation, chemotherapy and palliative care. Curative surgical resection of the tumor happens in localized non-small cell carcinoma cases. Resection is performed, accompanied by clearing of the lymphatic basins.

Since small cell carcinoma is usually already advanced at its diagnosis, surgical treatment with subsequent chemotherapy, aiming at cure, is applied only at an early stage. In some instances, combined chemotherapy and radiotherapy can be carried out preoperatively.

Small cell carcinoma is treated with radiation therapy using a megavolt technique with a dose that destroys the tumor – 50-60 Gy. In this case, the skull is also irradiated prophylactically. Polychemotherapy in combination with radiotherapy in small cell carcinoma in the case of the limited disease leads to a complete cure in 5-10% of cases.

Where there is no cure due to the stage of the disease, there is a need for palliative treatment.

It includes radiation, chemotherapy, administration of bisphosphonates in the presence of bone metastases, and analgesic preparations for cancer pain.

Lung Cancer Prevention – How to Protect Ourselves?

It is essential to avoid carcinogenic substances and smoking. Statistics show that there would be 1/3 less cancer globally if all smokers stopped smoking.

What are the Recommendations after the Diagnosis?

Prognosis depends entirely on early diagnosis. Unfortunately, nearly 2/3 of patients at diagnosis are unsuitable for surgery. The behavior and prognostic factors depend on the following:
-the histological type
-the disease stage
-the patient’s general condition
-immunological status.

Early diagnosis of first-stage squamous cell carcinoma, for example, without lymph node involvement, predicts survival after five years in about 60% of cases. As the disease progresses (2nd – 3rd stage), this percentage sharply decreases. In the remaining histological types, the prognosis for cure is unfavorable, especially in small-cell carcinoma.

Posted on

Buy MOTS-c Online – Order Now!

Buy MOTS-c OnlineAre you in the research sector and looking to buy MOTS-c online from a reputable source? We supply the best quality research chemicals from the legit US-licensed medical researchers Peptide Sciences. You can purchase research peptide MOTS-c directly from our online store today. MOTS-c, or the Mitochondrial-Derived Peptide, increases metabolic homeostasis to lose weight and improve Insulin resistance. In studies, MOTS-c is an exceptional peptide with benefits such as:

-Increasing metabolic function
-Help with weight loss
-Regulate mitochondrial energy
-Improve the regulation of glucose
-Improve bone health and stop osteoporosis

<<Buy MOTS-c Online – Order Now MOTS-c Vial 5mg and MOTS-C 10mg Here!>>

Where to Buy MOT-c?

We supply the best research peptide MOTS-c online for study use only. Our research products are tested with the latest technology and are pure and safe. In addition, they are made in the USA by leading manufacturer Peptide Sciences. We guarantee a first-class service from an easy online ordering system, a choice of payments, and fast shipping. There is the chance to buy some of our best buys in bulk, and you can save on postage on orders above $200. (USA only).

What is MOTS-c Supplement?

MOTS-c is a relatively new research peptide of 16 amino acids made from the mitochondrial gene. From intense studies, mitochondria play a big part in controlling energy production. MOTS -c maintains regular metabolic functions in the body, changing glucose into usable energy. The first studies indicate MOTS -c improves control over blood sugar levels in patients with type 2 diabetes and obesity. Studies confirm skeletal muscle is the primary target tissue of MOTS-c. The process is because lean muscle intensifies insulin sensitivity and boosts glucose in muscle cells from actioning the AMPK route while not increasing insulin.

MOTS-c Diabetes

Generally, experts describe MOTS-c as an exercise mimic because it has the same effect on the body as exercise. It increases glucose usage without promoting insulin.

In 1999 experts found AMPK or AMP‐activated protein kinase was the primary key for metabolism and regulation of glucose and fat metabolism. Since then, it has been the main aim of therapy interference from metabolic problems like type 2 diabetes.

Research MOTS-c Peptide Review

The research peptide MOTS-c derives from mitochondrial-derived protein and controls ATP. It boosts insulin sensitivity by lowering glucose broken down by adipose cells. Numerous studies show that MOTS-c can reduce fatty liver disease, making it a possible type 2 diabetes treatment. It does this by encouraging a positive shift in insulin sensitivity, making diet and exercise guide muscles to regain regular function. These processes lower insulin levels and leptin resistance.

Weight Loss with MOTS-c Before and After

Further research shows that MOTS-c is effective in weight loss. It does this by AMP working on cellular energy, with cells actioning AMP when energy levels are low. The AMPK begins in the body after calorie restriction and exercise. In research, the substances that ignite AMPK to work also improve general well-being, reverse diseases such as diabetes, heart disease, and mitochondrial diseases, and increase life expectancy.

The body needs a metabolism that works adequately with regular insulin and glucose regulation, proper energy use, and proper mitochondria function. Experts find that the artificial peptide MOTS-c can boost metabolic homeostasis and lower obesity and insulin resistance. Mitochondria also play a crucial role in determining metabolic flexibility.

Osteoporosis – MOTS-c Benefits

Osteoporosis is another factor of aging. The disease weakens bones so much that they can easily fracture and break. Hips, back bones and wrists are most common to fail and break. Osteoporosis is a disease that creeps up and is often not noticed until a bone breaks. Yet this result will mean bones have been losing strength for years. Osteoporosis is a metabolic disease, and MOTS-c can act on cells to promote bone formation and improve stability.

Summary MOTS-c Benefits
-Promotes fatty acid metabolism in the liver
-Regulates mitochondrial energy
-Protects against age and diet-related weight gain and insulin resistance
-Promotes weight loss
-Improves fitness
-Prevents osteoporosis
-Increases cell production to make new bone

MOTS-c Peptide Price is competitive and available HERE NOW!






Posted on

Peptides in Cosmetics

Peptides in Cosmetics

Peptides in Cosmetics – In the last year, the peptide serum has become one of the most sought-after beauty products. Everyone has heard and read something about peptides and knows that they are an essential part of anti-aging care. But did you know that the peptides used in cosmetics are in abundance, and each of them has a radically different effect? They serve as many functions in cosmetics as there are various skin problems.

In short, one serum may contain anti-pigmentation peptides, another – peptides for a lifting effect, and a third – for hydration. Therefore, you must first know what result you want to achieve, and then guide the selection of the most suitable peptides for the purpose. In the article we describe what the different types are and what to expect from them.


Peptides in cosmetics have a 20-30 year history. They are formed from short or long amino acids linked together. When joined in a group of two-three-four to ten amino acids, they form a peptide of a certain type. Namely, the connection of two amino acids is called a dipeptide, three amino acids connected is called a tripeptide, four is a tetrapeptide, and so on. And when the peptides bond with each other, they turn into proteins – a basic building block of the skin known as keratin.


Peptides play the role of “information agents” that carry information from one cell to another. What makes them so unique is that they signal cells to produce an element that has stopped or slowed down. For example, when collagen is broken down, natural peptides in the body signal cells in the skin to generate more collagen. And synthetic peptides developed for the cosmetics industry can mimic those naturally found in the skin. They signal to the skin that collagen is breaking down and new collagen production begins.

When peptides are missing in the skin, changes in its structure and appearance occur. Depending on their physiological effect, their roles can be:

  • Stimulants – improve skin regeneration
  • Neurotransmitters – increase the sensitivity threshold of the skin
  • Stabilizers – increase the antioxidant activity of the skin
  • Immunomodulators – increase the immune defense of the skin
  • Regulators of melanogenesis – to correct pigment spots
  • Peptides affecting microcirculation with an anti-edematous effect


Current research shows that all peptides have skin-restoring abilities if their formula is protected from breaking down after exposure to light and air, for example. Ironically, peptides can be hydrophilic, that is, unstable in water-based formulas. In addition, they can easily be broken down by the numerous enzymes in the skin and no longer have any benefits for it.

Knowledge of these inherent peptide weaknesses has led many companies to produce synthetic peptides in stabilized formulations. Only stable peptides can fully survive on the skin and smoothly reach their target, deep in the skin layers.

Here are the most common peptides in cosmetics and their names:

Carnosine – a dipeptide that is part of the body’s natural antioxidant system. It is responsible for neutralizing the molecule AGEs / Advanced Glycation End Products. These are responsible for the process of advanced glycation – an irreversible process that changes the structure of collagen and leads to its hardening.

Copper peptide /GHK-Cu, glycyl-L-histidyl-L-lysine is a copper peptide that accelerates the wound healing process. It has an anti-inflammatory effect by stimulating the synthesis of glycosaminoglycans and hyaluronic acid. It also plays the role of a powerful antioxidant.

Crystalide – a peptide that works in two directions. It balances and normalizes the cell renewal process, smoothing the skin surface. Plus, it stimulates the synthesis of a protein called α-crystallin, which is extremely important for achieving the much-desired “porcelain skin”.

Matrixyl 3000 /palmitoyl tetrapeptide-7 or Matrikyne is extensively studied for its ability to stimulate new production of type I and II collagen and fibronectin. It is important for skin density and elasticity. A peptide with a lifting effect, which is produced in the fibroblasts when the skin is damaged and strengthens its matrix. Matrikins are produced not only in case of damage, but also in the process of natural skin renewal.

Argireline /acetyl hexapeptide-8 is a synthetic polypeptide similar to botulinum toxin better known as Botox. But unlike Botox, it is safe to use and has no side effects. It prevents the transmission of a nerve impulse to the muscle and reduces the depth of wrinkles.

Don’t get carried away with the idea that there is a “best peptide” or combination of peptides. Dozens of remarkable peptides exist and more and more will be discovered and developed.